Marsh McLennan appoints Bruce Broussard to board of directors

NEW YORK - Global risk, strategy and people advisory firm Marsh McLennan (NYSE:MMC), a $105 billion market cap company currently trading near its 52-week low, announced Wednesday the appointment of Bruce Broussard to its board of directors, effective immediately.

Broussard, who served as Humana’s CEO from 2013 to 2024, brings over 30 years of healthcare leadership experience to the board. Before his tenure at Humana, he held various executive positions at McKesson Specialty/US Oncology, including CEO, Chairman, President and CFO.

With Broussard’s addition, Marsh McLennan’s board now consists of 12 directors.

H. Edward Hanway, Chair of Marsh McLennan’s Board, said the appointment reflects the company’s commitment to adding broad industry expertise to its governance team.

Marsh McLennan President and CEO John Doyle noted that Broussard’s background in insurance and healthcare, coupled with his experience as a chief executive and financial officer, would provide valuable perspective to the board.

Broussard currently serves on the boards of HP Inc., Cleveland Clinic and One Call. He is also active in various advocacy organizations, including The Business Council and the American Heart Association’s CEO Roundtable, and chairs the Board of Directors of the Trust for the National Mall.

Marsh McLennan operates in 130 countries through its four business units: Marsh, Guy Carpenter, Mercer and Oliver Wyman. The company generated $25.05 billion in revenue over the last twelve months, with a solid 44.3% gross profit margin and strong return on equity of 31%. For deeper insights into MMC’s financial performance and valuation metrics, check out the comprehensive Pro Research Report available on InvestingPro. The company employs more than 90,000 people globally.

In other recent news, Marsh McLennan reported its first-quarter 2025 earnings, with an adjusted earnings per share (EPS) of $3.06, slightly above the forecast of $3.03. However, the company’s revenue of $7.06 billion was just below the anticipated $7.09 billion. Marsh McLennan also announced a 10% increase in its quarterly dividend, raising it from $0.815 to $0.900 per share, payable in mid-August 2025. In terms of acquisitions, Marsh McLennan Agency acquired Excel Insurance, a Florida-based agency, to enhance its service offerings in South Florida. Additionally, Oliver Wyman, a subsidiary of Marsh McLennan, is set to acquire healthcare analytics firm Validate Health, aiming to strengthen its analytics and technology capabilities. Analyst firms have not recently upgraded or downgraded Marsh McLennan’s stock, but the company continues to focus on growth through strategic acquisitions. Marsh McLennan’s annual revenue exceeded $24 billion in the most recent fiscal year, reflecting its broad global operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.